Our material issues
Through our materiality assessment, we identify issues where we have the most potential to create value for stakeholders and society.
Every four years, we conduct a detailed assessment to identify our material issues. Results from this assessment inform our strategy and ESG reporting. The assessment sits alongside our regular risk analysis (see "Ethics, risk and compliance").
Our latest assessment, conducted in 2021, was based on a survey of more than 500 external and 12 000 internal stakeholders. Respondents were asked to rank the impact of Novartis across eight impact clusters. Follow-up interviews were conducted with 140 respondents. The results of this exercise can be seen in the chart on the right.
External stakeholders were drawn from our main stakeholder groups, including patients, customers, partners and shareholders. Internal stakeholders, including senior management, were drawn from across business divisions and functions.
Overall, these results were in line with the previous assessment carried out in 2017 and were consistent across stakeholder groups. Patient safety, access to healthcare, innovation and ethical business practices also ranked highly in our previous survey.
For full details of our materiality assessment, please see